中国畜牧兽医 ›› 2023, Vol. 50 ›› Issue (11): 4768-4775.doi: 10.16431/j.cnki.1671-7236.2023.11.043

• 基础兽医 • 上一篇    下一篇

犬脐带间充质干细胞联合滑车沟再造术治疗髌骨脱位的临床效果评估

何诗1, 冼伟杭1, 吴仲恒2, 陈胜锋1, 阮慧敏3, 叶彩灵3, 王粹琳3, 王丙云1   

  1. 1. 佛山科学技术学院生命科学与工程学院, 佛山 528231;
    2. 广州博仕动物医院, 广州 510000;
    3. 广东维赛生物科技有限公司, 佛山 528225
  • 收稿日期:2023-04-08 出版日期:2023-11-05 发布日期:2023-10-27
  • 通讯作者: 王丙云 E-mail:bywang63@163.com
  • 作者简介:何诗,E-mail:mslionaho@163.com。
  • 基金资助:
    广东省自然科学基金(2020A1515011110);广东省普通高校动物干细胞工程技术研究中心(2021GCZX006)

Therapeutic Clinical Effect of Canine UC-MSCs Combined with Trochlear Groove Reconstruction on Patellar Dislocation in Dogs

HE Shi1, XIAN Weihang1, WU Zhongheng2, CHEN Shengfeng1, RUAN Huimin3, YE Cailing3, WANG Cuilin3, WANG Bingyun1   

  1. 1. School of Life Science and Engineering, Foshan University, Foshan 528231, China;
    2. Doctor Veterinary Hospital of Guangzhou, Guangzhou 510000, China;
    3. Guangdong VetCell Biological Technology Co., Ltd., Foshan 528225, China
  • Received:2023-04-08 Online:2023-11-05 Published:2023-10-27

摘要: 【目的】探究犬脐带间充质干细胞(UC-MSCs)联合滑车沟再造术对髌骨脱位治疗的效果。【方法】将20只髌骨脱位患犬随机分为干细胞治疗组和常规手术组,每组10只。手术当天,干细胞治疗组关节腔注射0.5 mL UC-MSCs(106/kg)混悬液,常规手术组注入等量生理盐水,通过收集患犬基础信息、回访跟踪记录,检测血常规和血液因子含量以及影像学等方法评估犬UC-MSCs的治疗效果。【结果】与常规手术组对比,术后第1、7天干细胞治疗组白细胞介素-6(IL-6)含量极显著或显著降低(P<0.01;P<0.05),两组间转化生长因子-β1(TGF-β1)、基质金属蛋白酶13(MMP-13)及肿瘤坏死因子α(TNF-α)和白细胞总数、中性粒细胞总数均无显著差异(P>0.05)。术后第30天数字X线摄影复查结果显示,干细胞治疗组关节腔清晰,骨损位置有明显的软骨及骨组织生长,无再次脱出和关节炎等并发症。常规手术组的骨损伤处骨生长情况缓慢,2例患犬髌骨再次脱位(2/10)。【结论】滑车沟再造术后,在常规术后护理(使用抗炎、抗菌和止疼药物)条件下,关节腔内注射UC-MSCs能促进软骨和骨组织生长,降低再次脱出发生的风险。UC-MSCs联合滑车沟再造术能提升犬髌骨脱位的临床治疗效果。

关键词: 犬脐带间充质干细胞; 滑车沟再造术; 髌骨脱位; 骨修复

Abstract: 【Obgective】 The aim of this study was to investigate the therapeutic clinical effect of canine umbilical cord mesenchymal stem cells (UC-MSCs) combined with trochlear groove reconstruction in the treatment of patellar dislocation.【Method】 Twenty dogs with patellar dislocation were randomly divided into stem cell treatment group and conventional surgery group, with 10 dogs in each group. On the day of surgery, 0.5 mL UC-MSCs (106/kg) suspension was injected into the joint cavity of the stem cell treatment group, and the same amount of normal saline was injected into the conventional surgery group.The therapeutic effect of UC-MSCs was evaluated by collecting the basic information of the affected dogs, follow-up records, blood routine and blood factor content detection, and imaging methods. 【Result】 Compared with the conventional surgery group, the interleukin-6 (IL-6) content in the stem cell treatment group was extremely significantly or significantly decreased at the 1st and 7th day after surgery (P<0.01 or P<0.05).There were no significant differences in transforming growth factor-β1 (TGF-β1), matrix metalloproteinase 13 (MMP-13), tumor necrosis factor α (TNF-α), total number of white blood cells and neutrophils between two groups (P>0.05). Upon reassessment 30 days postoperatively via digital X-ray, the stem cell treatment exhibited pronounced cartilage and bone regeneration at the bone lesion location, with no complications such as recurrence and arthritis observed.In the conventional surgery group, the bone growth at the bone injury site was slow, and 2 patients suffered from re-dislocation of patella (2/10).【Conclusion】 After trochlear groove reconstruction, intraarticular injection of UC-MSCs could promote cartilage and bone tissue growth and reduce the risk of recurrence under conventional post-operative care (anti-inflammatory, antibacterial, and pain reliever).UC-MSCs combined with trochlear groove reconstruction could improve the clinical treatment of patellar dislocation in dogs.

Key words: canine umbilical cord mesenchymal stem cells; trochlear groove reconstruction; patellar dislocation; bone repair

中图分类号: